GB2101888A - Vegetable/animal extracts - Google Patents

Vegetable/animal extracts Download PDF

Info

Publication number
GB2101888A
GB2101888A GB08219635A GB8219635A GB2101888A GB 2101888 A GB2101888 A GB 2101888A GB 08219635 A GB08219635 A GB 08219635A GB 8219635 A GB8219635 A GB 8219635A GB 2101888 A GB2101888 A GB 2101888A
Authority
GB
United Kingdom
Prior art keywords
tissue
extraction
process according
ethanol
dried
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB08219635A
Inventor
Bedrich Dolezel
Gabriel Urbanek
Zdenek Rejdak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vysoka Skola Chemicko Technologicka V Praze
Original Assignee
Vysoka Skola Chemicko Technologicka V Praze
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vysoka Skola Chemicko Technologicka V Praze filed Critical Vysoka Skola Chemicko Technologicka V Praze
Publication of GB2101888A publication Critical patent/GB2101888A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56Materials from animals other than mammals
    • A61K35/60Fish, e.g. seahorses; Fish eggs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/38Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

For the therapy and regeneration of cells in live organisms by extraction from an animal or vegetable tissue, the tissue is exposed to ethanol for 3 to 100 days at a temperature of 10-100 DEG C, preferably 70-85 DEG C. The thus obtained extract is further concentrated to 5-50% of its original volume; the concentrate is precipitated by ether; the precipitate is washed with ether, dried and dissolved in a solvent. Prior to extraction by 40-98% ethanol, the tissue is dried and comminuted. The ethanol extraction can also be performed in a multistage process, the extracts from the individual stages being intermixed before being concentrated. The animal tissue used is bovine blood or a mixture of cow and bull blood which, prior to its extraction by 85-98% ethanol, is dried at a temperature of 30-100 DEG C in an air stream, herring spawn or sperm; and the vegetable tissue is St John's wort herb.

Description

SPECIFICATION Tissue preparation This invention relates to a process for producing the tissue preparation for the therapy and regeneration of cells in live organisms by the action of a substance upon the macroorganism terrain, said action being adequate having regard to the given organism status.
For the above purpose there have been used in the past coarse extracts of various tissues which provoked in the organism unwanted reactions, and some side effects, caused dosage problems and apart from this, led even to organism allergy symptoms. The heretofore adopted conception in the therapy has predominantly been of aggressive character. It has endeavoured above all to destroy a pathological malignant cell by means which are constituted in the present all-world practice by the so-called cytostatics. As is known, cytostatics are the most toxic chemotherapeutic substances of all in the medical practice since apart from antineoplastic effects thereof they tend simultaneously to damage healthy tissues, toxically influence mucuous membranes, suppress the growth of medulla, cause alopecia etc. Apart from this, their immunosuppressive and teratogeneous effects are also dangerous.
It is an object of the present invention to reduce or eliminate the disadvantage of the prior art as hereinabove set forth and to provide an improved process of producing a tissue preparation for the therapy and regeneration of cells in live organisms, the preparation being obtained by extraction from animal, orvegetal tissues by means of extraction agents.
According to the invention, in a process, the tissue is exposed to said extraction agent for 3 to 100 days at a temperature of 10 to 100"C, and the so obtained extract is precipitated by a solvent, the so obtained precipitate being washed by ether and dried, and the dried precipitate is dissolved in a solvent.
The tissue used in preferably animal tissue, e.g.
bovine blood or a mixture of cow and bull blood.
The extraction agent preferably comprises etha nol, and more especially 40-98% (e.g. 85-98%) ethanol.
Preferably the exposure time of the tissue to the extraction agent is 3-30 days and the temperature at which it is so exposed is 70-85 C.
The solvent used for said precipitation may be ether.
Prior to its extraction as aforesaid, the tissue may be physically and/or chemically treated, dried (e.g. at a temperature of 30-1 000C in an air stream) and crushed.
In order to obtain effective complexes of tissue preparations, various processes are chosen, from the simplest extraction by ethanol (possibly in various concentrations) up to the precipitation of such substance complexes by ether from concentrated ethanolic extracts, followed by washing through, drying and dissolving the dry matter. The ethanolic extraction is performed at different con centrations; with some of the preparations it is preferable to expose the tissues to 40% ethanol, with others up to 98% ethanol. The process is carried out in extraction vessels at a temperature of from 10 to 1 00 C. With some tissues a short-term extraction is preferred, which means 1-2 days, with others a long-term extraction for 7 to 30 days. One and the same dose of a starting material is extracted twice to eight times, or even more times.The two-to eightstage extracts obtained are always intermixed. The time intervals of the individual extraction stages are as follows; 1st and 2nd extractions 24 hours each 3rd and 4th extraction 4 days together 5th and 6th extraction 10 days together 7th and 8th extraction 14 days together With some of the extracts the above intervals of the first, eighth and tenth extraction are reduced to 8 to 24 hours per step.
Prior to the ethanolic extraction, the initial tissue is ground, dried and again comminuted. For this purpose there are used a disintegrator and an electric hot air drier in which a temperature of from 30 to 100"C prevails. Qualitative differences among various tissue preparations are given by various intitial materials to be exposed to an extraction agent, by different extraction stages, or by different precipitation of ethanolic extracts as well as by other steps such as drying the dry matter and exposing it to further solvents.
Bovine blood is the most commonly used initial tissue for obtaining various tissue preparations to exhibit various effects. There is used a mixture of cow and bull blood obtained fresh in slaughterhouse from healthy individuals subjected to a veterinary pre-examination. Such blood, spread on trays in layers up to 2 cm thick is dried in a hot air drier at a temperature of from 30 to 1000C. Then it is put in an extractor and extracted by 85 to 98% ethanol. As hereinabove set forth, the extraction takes place in several stages, depending upon the orientation of the preparation to an actual nosological unit. The individual extracts are united and concentrated to one tenth up to one hundredth of the original volume. The feed of the initial material is in a ratio of 1:5 to 1 :10 relative to the extraction agent.By applying the preparations produced as hereinbefore referred to, it is possible to obtain some beneficial effects such as an improvement of the entire patient's status, an improvement of the blood count picture, pain mitigation, psychic relief, soporific and appetizing effects, sometimes even a stabilization of the disease, inhibitions of the tumor growth up to the repression and halting thereof. Further there may be achieved a positive influence on the postactinic syndrome, prolongation of life under bearable conditions (tissue preparations from bovine blood).
In the case of obliterating diseases of peripheral arteries caused by trophic changes, such as gangrene (M. Buerger, M. Raynaud) as well as in the case of obliterating endarteritis, the preparation widens the peripheral arteries, improves their trophics, eases pain, exhibits antiinflammatory effects whereby it suppresses completely the patho logical process, even serious gangrenes and ischemical syndromes. (Combinations of tissue preparations from blood and from Hypericum perforatum St.-John's-wort). In the case of chronic gynaecological inflammations and with degenerative articulation diseases, the tissue preparation of the invention made from herring sperm (milk) and spawn mitigates the general troubles and pain so that patients become more mobile.In the case of ulcerous diseases (ulcus ventriculi et duodeni), the tissue preparation made of perch stomach positively influences the pain, the healing process and the general patients' status. The tissue preparations of the invention are absolutely non-toxic and do not exhibit harmful effects during long-term applications.
The following examples are given as illustrative only without, however, limiting in any way the scope of the invention.
Example 1 An amount of 1000 millilitres of a mixture of cow and bull blood (50:50) was spread on stainless steel trays in a layer of about 2 cm and dried for 4 days in a hot air drier at a temperature of from 60 to 65"C.
Thus the dried blood was converted into a blackbrown amorphous mass which was then comminuted in a ball mill to a crystalline powder two be subjected to the process in an extractor (105 gram filling). A volume of 500 millilitres of ethanol was added and the extraction was performed in a water bath in the extractor for 6 days at a temperature of from 80 to 85"C; there were carried out four reaction stages, each with 500 ml of reaction agent (i.e. 2000 millilitres in total). The united or intermixed extracts were densified in vacuo on a glass evaporator to a volume of 100 ml which was allowed to stand for 24 hours and then filtered in vacuo through a filter paper. The filtrate was further evaporated in a laboratory distiller in a ground joint flask.The evaporator residue (red-brown-yellow amorphous mass) contained about 85% dry matter. Such a solution served as the initial solution for producing the tissue preparation to be applied to treat primary chronic progressive polyarthritis, PCP, whereby the following beneficial effects were exhibited: stopping of the process activity (SE value dropped to normal), removal of morning numbness and rest position pain, reduction or removal of oedemas, putting on weight, improvement of anemia status. If compared with the hitherto practised therapy methods, the therapy by applying the non-toxic harmless tissue preparation of the invention is of considerable advantage.
Example 2 A volume of 2000 millilitres of fresh bovine blood (cow and bull blood 50:50) was dried for 3 days on stainless steel trays in an electric hot air drier at a temperature of 80 + 1"C. Similarly to EXAMPLE 1, a charge of 200 grams was put in the extractor. An amount of 1000 ml of 95% ethanol was added thereto. There were performed 8 extraction stages: the first and the second for 2 days, the third and the fourth for 4 days, the fifth and the sixth for 10 days, and the seventh and eighth for 14 days, viz. 30 days in total. The individual extracts were always withdrawn whereupon they were intermixed, and the united extract was densified in vacuo on a glass evaporator.After the extract had been withdrawn, the same ethanol volume (1000 ml) was added to each charge, i.e. 8000 millilitres in total, whereupon the total amount was densified to 100 ml. To such an amount of evaporator residue a double volume of ether was added and the mixture was thoroughly shaken and intermixed. The thus arisen precipitate was filtered over a sinter disc, washed through by ether, sucked off, dried and dissolved in redistilled water. There was obtained an initial solution for the tissue preparation which exhibited remarkable results in the therapy of some types of malignant tumors of digestive organs and lungs, especially in combination with other tissue preparations.
Example 3 To a volume of 160 millilitres of ethanolic evaporation residue (see EXAMPLE 2) there was added the double ether volume and the thus obtained precipitate was separated. A residual alcoholic-etheric solution was filtered, densified on a circulatory evaporator and finally in a distillatorto a dense extract which was then subjected to further vacuum evaporation in a water bath until an evaporation residue in the form of a red-brown viscous mass was obtained; the latter was finally dissolved in ethanol (18 grams of residue in 300 ml). Such an ethanolic solution was used as the basic solution for the tissue preparation to be applied to the therapy of blood vessel diseases.
Example 4 Quickly treated frozen and unsalted herring spawn and sperm (milk), once washed through, were dried for 2-3 days fresh in a vacuum drier at a temperature of about 75rC. The dry matter was ground and stored in cans. A homogeneous sample was withdrawn to determine histamine. As charge there was was used the amount of 1000 grams of dried spawn and sperm (milk), of herring whereupon 3000 millilitres of ethanol was added to the extractor contents. The latter was then extracted for 24 hours at a temperature of from 75 to 80cm, a solution above the deposit was withdrawn (about 1000 ml) and the same amount of 95% ethanol (1000 ml) was added again.
This was repeated in six stages of one day each. The intermixed extracts were evaporated on a circulators evaporator and the residue was densified to 200 ml of the solution. The latter was then precipitated by a half up to the same ether volume, and the separated precipitate was filtered and dissolved in redistilled water to give about 10% of the solution. Yield: one percent of dry matter, i.e. 10.0 grams. Ten percent initial solution served for producing a tissue prepara tion which beneficially influenced chronic degenerative osteoarth roses irrespective of the localisation; gonarthrosis (knee joint), coxarthrosis (hip joint), spondylarthrosis (spinal joints) and other joint diseases. The preparation is of considerable importance since, in contradistinction of other remedies to be applied in case of the above indications, it is effective and fully non-toxic. Apart from this it exhibits positive effects on pains and on general status so that patients are more mobile and able to work.
Example 5 To an amount of 1500 grams of dried St.-John'swort herb (Herba Hyperici perforati) a volume of 12.5 litres of 50% ethanol was added. The extraction took place for 30 days under agitation at a temperature of from 20 to 22"C in a stoneware jar provided with an outlet. After maceration had been terminated, a clear extract was separated over gauze and the residual herb was washed through with 50% ethanol until the solution became tinted. The extract was densified on a glass evaporator to a syrupy consistency and dried in a vacuum drier at a temperature of from 40 to 60"C. The drying period took about 5 days. The yield of dry evaporation residue amounted to about 10%, i.e. 150 grams.The perfectly dried residue was crushed on a dish and digested at a temperature of from 20 to 22 C by 0.3% phenolic water for about 2 weeks with frequent agitation (Aqua redestilata).
Firstly digestion of the dry residue by 95% alcohol was carried out (the evaporation residue was overlayered to about 5 cm above the solid substance) whereupon the digestion by ether followed, the two digestion steps having each taken 5 hours. The solution was then decanted and filtered. The residue was overflowed again by phenolicwater (first time: 700ml; second time: about 230-300 ml) and stirred for about 3 hours. The two solutions were united, and after filtration, allowed to stand for 6 weeks at room temperature. After this time interval, the solution was filtered over a sinter disc No. 3. In this way, there was obtained a volume of about 1000 millilitres of yellow-brown basic solution for the production of tissue preparation from St.John'swort which exhibited a polyvalent antiinflammatory and general effect.
It particularly is designed for treating chronic gynaecological inflammations, especially resistant adnexal chronic infiltrates (inflammatory tumors), in combination with the blood tissue preparation, and as a regenerative component to treat inflammatory and degenerative processes of liver cells. Apart from its therapeutic effects, the important advantage of the preparation consists in that it is fully non-toxic and has no side effects. On the contrary, it positively influences the patient's general status.
The method of producing the tissue preparation according to the invention for the therapy and regeneration of cells in live organisms is advantageous in case of all the indications where degenerative and inflammatory processes are concerned. A particular advantage consists in that it makes it possible to obtain, by a selective or multistage extraction, complexes of physiologically effective substances which are fully non-toxic, exhibit no side effects, are precisely dosable, effective in very low concentrations and oriented to particular indications.

Claims (15)

1. A process for producing a tissue preparation from vegetal or animal tissue by extraction from such tissue by an extraction agent, wherein the tissue is exposed to said extraction agent for 3 to 100 days at a temperature of 10 to 1000C, and the so obtained extract is precipitated by a solvent, the so obtained precipitate being washed by ether and dried, and the dried precipitate is dissolved in a solvent.
2. A process according to Claim 1, wherein said tissue is an animal tissue.
3. A process according to Claim 2, wherein the animal tissue comprises bovine blood or a mixture of cow and bull blood.
4. A process according to any one of the preceding claims, wherein said extraction agent is ethanol.
5. A process according to any one of the preceding claims, wherein the temperature at which the tissue is exposed to said extraction agent is between 70 and 85"C.
6. A process according to any one of the preceding claims, wherein the exposure time of said tissue to said extraction agent is between 3 and 30 days.
7. A process according to any one of the preceding claims, wherein the solvent by which the concentrated extract is precipitated is ether.
8. A process according to any one of the preceding claims, wherein said extraction agent comprises 40-98% ethanol.
9. A process according to any one of the preceding claims, wherein said extraction agent comprises 85-98% ethanol.
10. A process according to any one of the preceding claims, wherein prior to its extraction by said extraction agent, the tissue is physically and/or chemically treated, dried and crushed.
11. A process according to any one of the preceding claims, wherein priorto its extraction by said extraction agent, the tissue is dried at a temperature of 30-1 000C in an air stream.
12. A process according to any one of the preceding claims, wherein prior to being precipitated by said solvent, the tissue is concentrated to 5-50% of its original volume.
13. A process according to any one of the preceding claims, wherein the extraction by said extraction agent is performed in a plurality of stages.
14. A process according to Claim 1 and substantially as hereinbefore described with reference to any one of Examples 1 to 5.
15. A tissue preparation when produced by a process according to any one of the preceding claims.
GB08219635A 1981-07-10 1982-07-07 Vegetable/animal extracts Withdrawn GB2101888A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CS815343A CS228038B1 (en) 1981-07-10 1981-07-10 Production of tissue preparation

Publications (1)

Publication Number Publication Date
GB2101888A true GB2101888A (en) 1983-01-26

Family

ID=5398144

Family Applications (1)

Application Number Title Priority Date Filing Date
GB08219635A Withdrawn GB2101888A (en) 1981-07-10 1982-07-07 Vegetable/animal extracts

Country Status (5)

Country Link
JP (1) JPS5832824A (en)
CS (1) CS228038B1 (en)
DE (1) DE3225597A1 (en)
FR (1) FR2509176A1 (en)
GB (1) GB2101888A (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997013489A2 (en) * 1995-09-29 1997-04-17 Dr. Willmar Schwabe Gmbh & Co. Stable extract of hypericum perforatum l., process for preparing the same and pharmaceutical compositions
US6238671B1 (en) * 1998-04-22 2001-05-29 Bionorica Arzneimittel Gmbh Process for the gentle recovery of extract fractions from hypericum, pharmaceutical preparations containing the same and their use
US6241988B1 (en) 1997-04-08 2001-06-05 Dr. Willmar Schwabe Gmbh & Co. Stable extract of hypericum perforatum L., a method for producing the same, and corresponding pharmaceutical preparations
WO2010097060A3 (en) * 2009-02-26 2010-10-14 Svus Pharma A.S. A method of biotechnological production of bovine hemoderivative and use of bovine hemoderivative

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0671237B2 (en) * 1988-09-16 1994-09-07 日本ビクター株式会社 High efficiency coding system
JP2646921B2 (en) * 1991-11-15 1997-08-27 日本ビクター株式会社 Adaptive quantizer
DE4344468A1 (en) * 1993-12-22 1995-07-06 Heilscher Karl Prof Dr Sc Prodn. of powder prods. from fresh fruit and vegetables

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997013489A2 (en) * 1995-09-29 1997-04-17 Dr. Willmar Schwabe Gmbh & Co. Stable extract of hypericum perforatum l., process for preparing the same and pharmaceutical compositions
WO1997013489A3 (en) * 1995-09-29 1997-08-14 Schwabe Willmar Gmbh & Co Stable extract of hypericum perforatum l., process for preparing the same and pharmaceutical compositions
US6280736B1 (en) * 1995-09-29 2001-08-28 Ur. Willmar Schwabe Gmbh & Co, Stable extract of Hypericum perforatum L.,process for preparing the same and pharmaceutical compositions
CN1087943C (en) * 1995-09-29 2002-07-24 威廉施瓦布博士有限公司 Stable extract of hypericum perforatum L., process for preparing the same and pharmaceutical compositions
US6241988B1 (en) 1997-04-08 2001-06-05 Dr. Willmar Schwabe Gmbh & Co. Stable extract of hypericum perforatum L., a method for producing the same, and corresponding pharmaceutical preparations
US6238671B1 (en) * 1998-04-22 2001-05-29 Bionorica Arzneimittel Gmbh Process for the gentle recovery of extract fractions from hypericum, pharmaceutical preparations containing the same and their use
WO2010097060A3 (en) * 2009-02-26 2010-10-14 Svus Pharma A.S. A method of biotechnological production of bovine hemoderivative and use of bovine hemoderivative
US20120070463A1 (en) * 2009-02-26 2012-03-22 Svus Pharma A.S. Method of biotechnological production fo bovine hemoderivative and use of bovine hemoderivative
US9029079B2 (en) 2009-02-26 2015-05-12 Svus Pharma A.S. Method of biotechnological production of bovine hemoderivative
EA021229B1 (en) * 2009-02-26 2015-05-29 Свус Фарма А.С. A method of biotechnological production of bovine hemoderivative

Also Published As

Publication number Publication date
CS228038B1 (en) 1984-05-14
DE3225597A1 (en) 1983-02-03
FR2509176A1 (en) 1983-01-14
JPS5832824A (en) 1983-02-25

Similar Documents

Publication Publication Date Title
GB2101888A (en) Vegetable/animal extracts
CH653349A5 (en) POLYSACCHARIDES, THEIR PRODUCTION AND THE THERAPEUTIC COMPOSITIONS CONTAINING THEM.
Ajibade et al. Histopathological and toxicological effects of crude saponin extract from Phyllanthus niruri, L (Syn. P. franternus. Webster) on organs in animal studies
CN108542926A (en) The preparation method and pharmaceutical composition of a kind of purslane extract and its application
US1469994A (en) Extract obtainable from the mammalian pancreas or from the related glands in fishes, useful in the treatment of diabetes mellitus, and a method of preparing it
FI64892B (en) FRAMEWORK FOR ANTI-SORGHY EFFECTS
JPH1192391A (en) Pharmaceutical composition effective for preventing or treating dysmenorrhea
MacDougall et al. Effect of initial drying temperature on the apparent lignin content of plant tissues
US2464240A (en) Therapeutic material and method of obtaining the same
JPS58194818A (en) Separation of water-soluble polysaccharide and fiber from cactus
KR20210065633A (en) Composition for improving liver injury and liver disease comprising flower of Rosa rugosa Thunberg and Cinnamomum cassia PRESL
RU2771028C1 (en) Method for producing a medicinal product exhibiting hepatoprotective and antihepatotoxic actions
AT392003B (en) METHOD FOR PRODUCING A PARTICULARLY FOR Wounds Healing Or For Treatment In Geriatrics, Active Ingredients From Mammalian Blood By PAPAINE HYDROLYSIS AND A PREPARATION CONTAINING SUCH AN ACTIVE SUBSTANCE
RU2800375C1 (en) Angent with creatininuretic action
RU2045271C1 (en) Method for preparing agent having antitumoral activity
DE3004018C2 (en)
US2099708A (en) Therapeutic product and method of making same
CN109125703A (en) A kind of pharmaceutical composition and preparation method thereof for treating vaginitis
Bay et al. Digitalis, a preliminary investigation
JPS61200923A (en) Substance having antiallergic action and production thereof
DE576446C (en) Process for obtaining an inactivator of a bloodstream hormone
DE633156C (en) Method of obtaining a cure for tumors
JP5173432B2 (en) Herbal formulation for joints
DE718245C (en) Method for determining the presence of malignant tumors
AT224807B (en) Method for obtaining a new anti-tumor polysaccharide

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)